Leadership Change at May Health with Colby Holtshouse
May Health, a trailblazer in developing treatments for women with Polycystic Ovary Syndrome (PCOS), has appointed Colby Holtshouse as its new President and CEO. This transition comes as the company intensifies its efforts on clinical evaluations of its innovative Ovarian Rebalancing™ technology. This innovative procedure is aimed at restoring ovulation in women affected by PCOS, which has become a primary factor in infertility cases.
Welcoming a Visionary Leader
Colby Holtshouse brings extensive experience in the medical technology field, particularly in women's health. She previously served in significant roles at Organon (NYSE: OGN), Alydia Health, and Pelvalon, making her versed in launching cutting-edge technologies. Dr. Robert Auerbach, chairman of May Health, expressed enthusiasm for Holtshouse's leadership during a pivotal time for the company.
Focus on Clinical Advancement
The core of May Health’s mission is to complete the REBALANCE clinical study, a crucial investigational device exemption (IDE) trial designed to support marketing authorization for their ovarian rebalancing procedure. Auerbach emphasized the importance of this study, highlighting its potential to provide this therapy to millions of women facing challenges with PCOS-related infertility.
Innovative Approach to PCOS
PCOS affects roughly 10% of women, contributing to serious health issues, including infertility and other metabolic concerns. May Health’s Ovarian Rebalancing procedure uses a specialized ultrasound-guided, transvaginal technique employing radio frequency energy to target and ablate problematic ovarian tissues. This one-time, minimally invasive procedure allows for same-day recovery and return to daily activities, making it a promising option for those resistant to standard oral medications.
Encouraging Outcomes from Clinical Trials
Encouraged by favorable outcomes from clinical feasibility studies completed in various regions, including the U.S. and parts of Europe, Holtshouse looks forward to the progression of the REBALANCE study. With the FDA’s oversight in this process, she anticipates substantial advancements for physicians and patients seeking new options for managing PCOS-related infertility.
About May Health
Founded in 2012 and based in both Paris and California, May Health is dedicated to revolutionizing women's health through innovative medtech solutions. The company’s advanced treatment approach aims to effectively address PCOS, which remains a common challenge faced by women globally. After securing substantial funding through successful investment rounds, May Health is positioned for impactful breakthroughs in women's health.
Significance of Ovarian Rebalancing Technology
The Ovarian Rebalancing™ technology signifies a major step towards personalized patient care and reveals the company's commitment to addressing infertility issues linked to hormonal imbalances. The procedure's design focuses on both efficacy and patient comfort, showcasing the evolving landscape of medical interventions tailored for women.
Frequently Asked Questions
What does the leadership change mean for May Health?
The appointment of Colby Holtshouse signals a strategic direction for May Health aimed at enhancing clinical outcomes and accelerating the development of its innovative technologies.
What is the Ovarian Rebalancing technology?
This investigational procedure seeks to restore ovulation in patients with PCOS by targeting excess androgen-producing ovarian tissues through a minimally invasive technique.
How does May Health support women with PCOS?
May Health focuses on creating advanced treatment options for women facing fertility challenges due to PCOS, ensuring they have access to effective solutions.
What is the significance of the REBALANCE study?
The REBALANCE study is crucial for gaining FDA approval for the Ovarian Rebalancing procedure, aiming to validate its effectiveness for widespread clinical adoption.
Who are key figures in May Health?
Colby Holtshouse, as the new CEO, along with Dr. Robert Auerbach and Antoine Papiernik, are pivotal in steering the company towards its goals in women's health advancements.
